Thank you to our speakers, sponsors, and delegates who joined us in September for the summit! If you are interested in the 2025 event, please register your interest below to receive updates on the meeting!
With Karuna’s schizophrenia program coined as the most anticipated drug launch of 2024, and 2023 bringing brand new regulatory guidance, surging investment has reinvigorated the space with new targets, mechanisms, and technologies to transform the mental health treatment landscape.
Capitalizing on a new wave of pipeline momentum, the 7th Neuropsychiatric Drug Development Summit returned as the industry’s premier gathering, showcasing the latest circuit-based target innovation, EEG and digital biomarker data, in vivo and in vitro model advances, pioneering precision psychiatry approaches and more.
Attendees joined discovery, preclinical, translational, clinical, regulatory, and commercial experts from Karuna, Janssen, AbbVie, Otsuka, Alto Neuroscience, Lykos, Lundbeck, Compass, Biogen, DelixTherapeutics, Boehringer Ingelheim, and more as they addressed biopharma’s most pressing challenges in a collaborative atmosphere to accelerate the race to approval for transformative neuropsychiatric candidates.
Our 2024 Expert Speaker Faculty Included:
Cornelia Dorner-Ciossek
Head of Digital Health TA CNS Retinopathies Emerging Areas
Boehringer Ingelheim
Wayne Drevets
Vice President, Disease Area Team Leader, Neuroscience
Johnson & Johnson Services, Inc
Access the Comprehensive Event Guide With 35+ Speakers, 2 Tracks of Content, 4 Pre-conference Workshops & More!
Previous Attending Companies Include:
“An engaging and interactive conference, providing an opportunity for R&D leaders in neuropsychiatry to roll up their sleeves and discuss issues that we are collectively facing in this rapidly evolving field.”
Aaron Koenig, Chief Medical Officer, Delix Therapeutics
“The upcoming years look promising for the field of psychiatry. According to J.P. Morgan’s Annual Biopharma Licensing and Venture Report, 2023 witnessed significant venture capital investment in neuroscience, a trend that is expected to persist. Accompanying this surge is a notable increase in investments in mental health apps and AI-driven mental health solutions. I am eager to learn how drug developers plan to capitalize on this favorable landscape.”
Snezana Milanovic, Senior Director, TMED & Early Development, Sumitomo Pharma America
Our 2024 Partners Included:
Other Events in the World CNS Series:
